Date: 2015-10-28
Type of information: Collaboration agreement
Compound: structural, biological and therapeutic information in relation to various therapeutic targets and related assays
Company: C4X Discovery (UK) University of Oxford’s Structural Genomics Consortium department (UK)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On October 28, 2015, C4X Discovery, a leader in rational drug discovery and design, announced that it has entered into a research collaboration with the University of Oxford’s Structural Genomics Consortium department (“SGC-Oxford”). SGC-Oxford is part of the Nuffield Department of Clinical Medicine and consists of around 100 scientists who collaborate widely with major pharmaceutical companies and the worldwide academic network. Under the terms of this collaboration, C4XD will be granted access to structural, biological and therapeutic information that SGC-Oxford holds in relation to various therapeutic targets and related assays, as well as initial ‘hit’ molecules that SGC-Oxford has identified against these targets. C4XD’s expertise in ligand design will be used to complement SGC-Oxford’s expertise in x-ray crystallography, screening and chemical biology in the identification of new and improved hit molecules against the SGC-Oxford targets. Improvements made to SGC-Oxford’s existing hit molecules will be the exclusive property of SGC-Oxford, which will make them freely available in line with SGC-Oxford policy, while new compounds independently identified by C4XD will belong to C4XD. There are no cash payments due under the collaboration.
Financial terms:
Latest news:
